International Journal of Urology | 2019
Editorial Comment to Impact of post‐void residual urine volume on intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma
Abstract
1 Azemar MD, Comperat E, Richard F, Cussenot O, Roupret M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol. Oncol. 2011; 29: 130–6. 2 Seisen T, Granger B, Colin P et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur. Urol. 2015; 67: 1122–33. 3 Kang D, Chokkalingam AP, Gridley G et al. Benign prostatic hyperplasia and subsequent risk of bladder cancer. Br. J. Cancer 2007; 96: 1475–9. 4 Matsumoto S, Shimizu N, Hanai T, Uemura H, Levin R. Bladder outlet obstruction accelerates bladder carcinogenesis. BJU Int. 2008; 103: 1436–9. 5 Ito A, Shintaku I, Satoh M et al. Prospective randomized phase II trial of a single early intravesical instillation pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for UUT-UC: The THP Monotherapy Study Group Trial. J. Clin. Oncol. 2013; 31: 1422–7. 6 Nagashima M, Araki A, Yanagisawa M et al. Effect of prophylactic intravesical instillation of pirarubicin to prevent recurrent bladder tumors following nephroureterectomy for upper urinary tract cancer.Hinyokika Kiyo 2013; 59: 213–6. 7 Yamamoto S, Sakamoto S, Imamura Y et al. Intravesical irrigation might prevent bladder recurrence in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Int. J. Urol. 2019; 26: 791–6. 8 Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993; 342: 1087–8. 9 Catto JW, Hartmann A, Stoehr R et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J. Urol. 2006; 175: 2323–30. 10 Takahashi S, Ichihara K, Hiyama Y, Uehara T, Hashimoto J, Masumori N. Do patients who complain of lower urinary tract symptoms frequently have clinically significant pyuria? J. Infect. Chemother. 2015; 21: 31–3. 11 Sazuka T, Kambara Y, Ishi T et al. Analysis of energy loss mediated by an alpha-1 blocker in patients with benign prostatic hyperplasia using a virtual urethra processed from an endoscopic video image. J. Endourol. 2012; 26: 1216–20. 12 Asimakopoulos AD, De Nunzio C, Kocjancic E, Tubaro A, Rosier PF, Finazzi-Agr o E. Measurement of post-void residual urine. Neurourol. Urodyn. 2016; 35: 55–7. 13 Haylen BT, Law MG, Frazer M, Schulz S. Urine flow rates and residual urine volumes in urogynecology patients. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1999; 10: 378–83. 14 Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int. J. Cancer 2002; 101: 1–6. 15 Levin RM, Chichester P, Hass MA, Gosling JA, Buttyan R. Obstructive bladder dysfunction: morphological, biochemical, and molecular changes. Eur. Urol. Suppl. 2002; 1: 14–20. 16 Levin RM, Chichester P, Levin SS, Buttyan R. Role of angiogenesis in the bladder s response to partial outlet obstruction: a review. Scand. J. Urol. Nephrol. 2004; 38: 37–47. 17 Chichester P, Lieb J, Levin SS, Buttyan R, Horan P, Levin RM. Vascular response of the rabbit bladder to short term partial outlet obstruction. Mol. Cell. Biochem. 2000; 208: 19–26. 18 Chichester P, Schr€oder A, Horan P, Levin RM. Vascular response of the rabbit bladder to chronic partial outlet obstruction. Mol. Cell. Biochem. 2001; 226: 1–8.